Haemonetics Corporation (NYSE:HAE) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Haemonetics Corporation (NYSE:HAE) have received an average recommendation of “Moderate Buy” from the eleven analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $77.1111.

Several equities research analysts have issued reports on the company. Citigroup raised their price target on Haemonetics from $64.00 to $70.00 and gave the company a “neutral” rating in a report on Thursday, May 28th. Robert W. Baird set a $67.00 target price on Haemonetics in a research note on Friday, May 8th. Weiss Ratings downgraded Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, May 21st. BTIG Research reiterated a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. Finally, Mizuho reduced their target price on shares of Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Monday, April 13th.

Haemonetics Stock Performance

HAE opened at $71.31 on Friday. Haemonetics has a 52-week low of $47.31 and a 52-week high of $87.32. The firm has a market capitalization of $3.24 billion, a PE ratio of 35.30, a PEG ratio of 1.41 and a beta of 0.56. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.87 and a current ratio of 2.95. The business’s 50-day simple moving average is $60.00 and its 200 day simple moving average is $67.27.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. The business had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, sell-side analysts expect that Haemonetics will post 5.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in HAE. Segall Bryant & Hamill LLC increased its stake in Haemonetics by 213.8% during the 1st quarter. Segall Bryant & Hamill LLC now owns 73,992 shares of the medical instruments supplier’s stock worth $4,170,000 after acquiring an additional 50,412 shares during the period. Amundi lifted its position in shares of Haemonetics by 111.2% during the 1st quarter. Amundi now owns 5,843 shares of the medical instruments supplier’s stock valued at $329,000 after acquiring an additional 3,077 shares during the period. EverSource Wealth Advisors LLC grew its holdings in shares of Haemonetics by 12.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,920 shares of the medical instruments supplier’s stock worth $108,000 after purchasing an additional 211 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Haemonetics by 15.2% in the first quarter. California State Teachers Retirement System now owns 52,606 shares of the medical instruments supplier’s stock worth $2,965,000 after purchasing an additional 6,931 shares during the period. Finally, Quantinno Capital Management LP raised its stake in Haemonetics by 438.0% in the first quarter. Quantinno Capital Management LP now owns 30,708 shares of the medical instruments supplier’s stock valued at $1,731,000 after purchasing an additional 25,000 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.